Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

S. Vincent Rajkumar, Ruben A. Mesa, Rafael Fonseca, Georgene Schroeder, Matthew F. Plevak, Angela Dispenzieri, Martha Q. Lacy, John A. Lust, Thomas E. Witzig, Morie A. Gertz, Robert A. Kyle, Stephen J. Russell, Philip R. Greipp

Research output: Contribution to journalArticle

270 Scopus citations

Abstract

Purpose: To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma. Experimental Design: Four hundred patients with the following disorders were studied: MGUS (76 patients); smoldering (indolent; early-stage) multiple myeloma (SMM; 112 patients); newly diagnosed, active multiple myeloma (MM; 99 patients); relapsed (advanced) multiple myeloma (RMM; 26 patients); and primary amyloidosis (AL; 87 patients). Forty-two normal control BM samples were studied for comparison. BM angiogenesis was studied in a blinded manner by immunohistochemical staining for CD34 to identify microvessels. Results: The median (range) microvessel density (MVD) per x400 high power field was 1.3 (0-11) in the controls, 1.7 (0-10) in AL, 3 (0-23) in MGUS, 4 (1-30) in SMM, 11 (1-48) in newly diagnosed MM, and 20 (6-47) in RMM; P < 0.001. MVD was significantly higher in MGUS, SMM, newly diagnosed MM, and RMM compared with controls and AL; P < 0.001. MVD was not significantly different between controls and AL. By grading, high-grade angiogenesis was present in 0% of controls and AL, 1% of MGUS, 3% of SMM, 29% of newly diagnosed MM, and 42% of RMM; P < 0.001. MVD correlated with the BM plasma cell labeling index (ρ = 0.46, P < 0.001) and BM plasma cell percentage (ρ 0.5, P < 0.001). Survival was 28 months in SMM and newly diagnosed MM with high-grade angiogenesis, compared with 53 months for those with low- and intermediate-grade angiogenesis; P = 0.02. Conclusions: BM angiogenesis progressively increases along the spectrum of plasma cell disorders, from the more benign MGUS stage to advanced myeloma, indicating that angiogenesis may be related to disease progression.

Original languageEnglish (US)
Pages (from-to)2210-2216
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number7
StatePublished - Jan 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis'. Together they form a unique fingerprint.

  • Cite this

    Rajkumar, S. V., Mesa, R. A., Fonseca, R., Schroeder, G., Plevak, M. F., Dispenzieri, A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Gertz, M. A., Kyle, R. A., Russell, S. J., & Greipp, P. R. (2002). Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 8(7), 2210-2216.